Lassa Fever - Drug Pipeline Landscape, 2023
Description
Lassa Fever - Drug Pipeline Landscape, 2023
Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is a hemorrhagic virus that can cause bleeding without any symptoms.
Lassa fever virus is a disease that is animal-borne or spread to humans from animals. It is spread to people through contact with household items, food, water, or air contaminated with the droppings or urine of infected multimammate rats (Mastomyces natalensis). The most common method of transmission is by consuming or inhaling rat urine or feces. It can also be spread through cuts and open sores. Person-to-person contact is possible via blood, tissue, secretions.
Symptoms of Lassa fever include bleeding in the gums, nose, difficulty in breathing, cough, vomiting and diarrhea, hepatitis, swollen face, hearing loss, high or low blood pressure, tremors and other CNS conditions.
Diagnostic tests for Lassa fever are laboratory-based. Lassa fever is diagnosed by using enzyme-linked immunosorbent serologic assays (ELISA). These detect IgM and IgG antibodies and Lassa antigens. Reverse transcription-polymerase chain reaction (RT-PCR) can also be used in the early stages of the disease. Immunohistochemistry stains performed on tissue specimens can be used to make a post-mortem diagnosis.
Rehydration and treatment of symptoms can improve the of survival if there is an early diagnosis. Intravenous ribavirin given early in the course of illness is an effective treatment, in addition to support of fluid and electrolytes, oxygenation, and blood pressure.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Lassa Fever treatment such as EBS-Lassa, GEO-LM01, Lassa Fever Vaccine and others. Key players involved in the development of therapies to treat Lassa Fever are Curevac AG, Emergent BioSolutions Inc, GeoVax Labs Inc, Medigen Inc, Zalgen Labs LLC and others. One drug is under clinical-stage Phase I clinical trials and four drugs are in preclinical and some other drugs are under discovery stages of development.
Report Highlights
Global Insight Service's, Lassa Fever - Drug Pipeline Landscape, 2023 report provides an overview of the Lassa Fever pipeline drugs. This report covers detailed insights on Lassa Fever drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Lassa Fever pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is a hemorrhagic virus that can cause bleeding without any symptoms.
Lassa fever virus is a disease that is animal-borne or spread to humans from animals. It is spread to people through contact with household items, food, water, or air contaminated with the droppings or urine of infected multimammate rats (Mastomyces natalensis). The most common method of transmission is by consuming or inhaling rat urine or feces. It can also be spread through cuts and open sores. Person-to-person contact is possible via blood, tissue, secretions.
Symptoms of Lassa fever include bleeding in the gums, nose, difficulty in breathing, cough, vomiting and diarrhea, hepatitis, swollen face, hearing loss, high or low blood pressure, tremors and other CNS conditions.
Diagnostic tests for Lassa fever are laboratory-based. Lassa fever is diagnosed by using enzyme-linked immunosorbent serologic assays (ELISA). These detect IgM and IgG antibodies and Lassa antigens. Reverse transcription-polymerase chain reaction (RT-PCR) can also be used in the early stages of the disease. Immunohistochemistry stains performed on tissue specimens can be used to make a post-mortem diagnosis.
Rehydration and treatment of symptoms can improve the of survival if there is an early diagnosis. Intravenous ribavirin given early in the course of illness is an effective treatment, in addition to support of fluid and electrolytes, oxygenation, and blood pressure.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Lassa Fever treatment such as EBS-Lassa, GEO-LM01, Lassa Fever Vaccine and others. Key players involved in the development of therapies to treat Lassa Fever are Curevac AG, Emergent BioSolutions Inc, GeoVax Labs Inc, Medigen Inc, Zalgen Labs LLC and others. One drug is under clinical-stage Phase I clinical trials and four drugs are in preclinical and some other drugs are under discovery stages of development.
Report Highlights
Global Insight Service's, Lassa Fever - Drug Pipeline Landscape, 2023 report provides an overview of the Lassa Fever pipeline drugs. This report covers detailed insights on Lassa Fever drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Lassa Fever pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
64 Pages
- 1. Introduction
- 1.1 Lassa Fever - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Lassa Fever
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Lassa Fever - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase I
- 5.1.1 EBS-Lassa
- 5.2 Early Stage Drugs-Preclinical
- 5.2.1 Lassa Fever Vaccine
- 5.2.2 Pan Lassa
- 5.2.3 VHFC Lassa Vaccine Program
- 5.3 Early Stage Drugs-Discovery
- 5.3.1 GEO-LM01
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Emergent BioSolutions Inc
- 9.2 GeoVax Labs Inc
- 9.3 Medigen Inc
- 9.4 Zalgen Labs LLC
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Lassa Fever
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details – EBS-Lassa/Emergent BioSolutions Inc
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Lassa Fever, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Lassa Fever, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Lassa Fever, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Lassa Fever, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Lassa Fever, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
